Connie Matsui Biography and Net Worth

Director of Sutro Biopharma

Connie Matsui has served as a member, and Chair, of our Board of Directors since June 2019 and brings over three decades of general management experience in the biotechnology industry. From 2004 to 2009, Ms. Matsui served in various leadership positions at Biogen Idec, Inc., including as Executive Vice President, Knowledge and Innovation Networks and Executive Committee member. Prior to that, Ms. Matsui served in various leadership positions at IDEC Pharmaceuticals, a predecessor of Biogen Idec, including Senior Vice President; Collaboration Chair for the late-stage development and commercialization of rituximab (tradenames: Rituxan® and MabThera®) in partnership with Roche and Genentech; and Project Leader for Zevalin®, the first radioimmunotherapy approved by the U.S. FDA. Prior to entering the biotechnology industry, Ms. Matsui worked for Wells Fargo Bank in general management, marketing, and human resources. Ms. Matsui currently serves on the board of directors of Artelo Biosciences, Inc. and has served on not-for-profit boards at the local, national, and global level. Ms. Matsui received a B.A. and an M.B.A. from Stanford University.

What is Connie Matsui's net worth?: The estimated net worth of Connie Matsui is at least $171.75 thousand as of October 15th, 2025. Ms. Matsui owns 5,000 shares of Sutro Biopharma stock worth more than $171,750 as of April 21st. This net worth estimate does not reflect any other assets that Ms. Matsui may own. Learn More about Connie Matsui's net worth.
How do I contact Connie Matsui?: The corporate mailing address for Ms. Matsui and other Sutro Biopharma executives is 310 Utah Avenue Suite 150, South San Francisco CA, 94080. Sutro Biopharma can also be reached via phone at (650) 392-8412 and via email at [email protected]. Learn More on Connie Matsui's contact information.
Has Connie Matsui been buying or selling shares of Sutro Biopharma?: Connie Matsui has not been actively trading shares of Sutro Biopharma over the course of the past ninety days. Most recently, on Wednesday, October 15th, Connie Matsui bought 5,000 shares of Sutro Biopharma stock. The stock was acquired at an average cost of $8.00 per share, with a total value of $40,000.00. Following the completion of the transaction, the director now directly owns 5,000 shares of the company's stock, valued at $40,000. Learn More on Connie Matsui's trading history.
Who are Sutro Biopharma's active insiders?: Sutro Biopharma's insider roster includes Connie Matsui (Director), David Pauling (Insider), and Nicki Vasquez (Insider). Learn More on Sutro Biopharma's active insiders.
Are insiders buying or selling shares of Sutro Biopharma?: During the last year, Sutro Biopharma insiders bought shares 5 times. They purchased a total of 11,175 shares worth more than $89,597.50. The most recent insider tranaction occured on October, 15th when insider Hans-Peter Gerber bought 1,700 shares worth more than $13,600.00. Insiders at Sutro Biopharma own 5.9% of the company. Learn More about insider trades at Sutro Biopharma.
Information on this page was last updated on 10/15/2025.

Connie Matsui Insider Trading History at Sutro Biopharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
10/15/2025	Buy	5,000	$8.00	$40,000.00	5,000

Connie Matsui Buying and Selling Activity at Sutro Biopharma

Sutro Biopharma Company Overview

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Today's Range

Now: $34.35

$33.61

$35.40

50 Day Range

MA: $22.82

$15.62

$34.58

2 Week Range

Now: $34.35

$5.60

$35.40

Volume

192,597 shs

Average Volume

173,493 shs

Market Capitalization

$569.18 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.31